{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:51:49Z","timestamp":1766400709375},"reference-count":99,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Obstetrics and Gynecology Clinics of North America"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.ogc.2013.03.007","type":"journal-article","created":{"date-parts":[[2013,5,10]],"date-time":"2013-05-10T08:45:13Z","timestamp":1368175513000},"page":"177-197","source":"Crossref","is-referenced-by-count":19,"title":["Human Papillomavirus Vaccination"],"prefix":"10.1016","volume":"40","author":[{"given":"Leda","family":"Gattoc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navya","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Ault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ogc.2013.03.007_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1363\/3600604","article-title":"Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000","volume":"36","author":"Weinstock","year":"2004","journal-title":"Perspect Sex Reprod Health"},{"issue":"4","key":"10.1016\/j.ogc.2013.03.007_bib2","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/infdis\/jir341","article-title":"Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006","volume":"204","author":"Hariri","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.ogc.2013.03.007_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.virol.2010.02.002","article-title":"Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments","volume":"401","author":"Bernard","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.ogc.2013.03.007_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A\u00a0review of human carcinogens\u2014Part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.ogc.2013.03.007_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479","article-title":"Chapter 1: human papillomavirus and cervical cancer\u2013burden and assessment of causality","author":"Bosch","year":"2003","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ogc.2013.03.007_bib6","article-title":"Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"10.1016\/j.ogc.2013.03.007_bib7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jnci\/djs491","article-title":"Annual report to the nation on the status of cancer, 1975\u20132009, featuring the burden and trends in human papillomavirus (HPV)\u2013associated cancers and HPV vaccination coverage levels","volume":"105","author":"Jemal","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.ogc.2013.03.007_bib8","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/oxfordjournals.aje.a010166","article-title":"Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis","volume":"151","author":"Myers","year":"2000","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.ogc.2013.03.007_bib9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jnci\/92.6.464","article-title":"Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica","volume":"92","author":"Herrero","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ogc.2013.03.007_bib10","series-title":"WHO\/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre)","author":"Castellsague","year":"2007"},{"issue":"12","key":"10.1016\/j.ogc.2013.03.007_bib11","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"issue":"2469","key":"10.1016\/j.ogc.2013.03.007_bib12","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1126\/science.95.2469.438","article-title":"A\u00a0new procedure for staining vaginal smears","volume":"95","author":"Papanicolaou","year":"1942","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.ogc.2013.03.007_bib13","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/jnci\/djs453","article-title":"Human papillomavirus vaccines for cervical cancer prevention: translating possibility into reality","volume":"104","author":"Sahasrabuddhe","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ogc.2013.03.007_bib14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/jnci\/djq562","article-title":"Human papillomavirus testing in the prevention of cervical cancer","volume":"103","author":"Schiffman","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9590","key":"10.1016\/j.ogc.2013.03.007_bib15","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.ogc.2013.03.007_bib16","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.vaccine.2005.09.002","article-title":"Immune responses to human papillomavirus","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"10.1016\/j.ogc.2013.03.007_bib17","article-title":"Chapter 1: HPV in the etiology of human cancer","volume":"24","author":"Mu\u00f1oz","year":"2006","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.ogc.2013.03.007_bib18","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1056\/NEJMp058171","article-title":"The promise of global cervical-cancer prevention","volume":"353","author":"Schiffman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ogc.2013.03.007_bib19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1086\/599988","article-title":"Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials","volume":"200","author":"Schiller","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.ogc.2013.03.007_bib20","first-page":"RR-2","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"CDC","year":"2007","journal-title":"MMWR Recomm Rep"},{"issue":"20","key":"10.1016\/j.ogc.2013.03.007_bib21","first-page":"626","article-title":"FDA licensure of bivalent human papillomavirus vaccine (HPV2 Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.ogc.2013.03.007_bib22","unstructured":"GlaxoSmithKline. CDC Advisory Committee recommends Cervarix to prevent cervical cancer in girls and young women. Available at: http:\/\/us.gsk.com\/html\/media-news\/pressreleases\/2009\/2009_us_pressrelease_10075.htm. Accessed November 10, 2009."},{"key":"10.1016\/j.ogc.2013.03.007_bib23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajog.2008.03.064","article-title":"The economic burden of noncervical human papillomavirus disease in the United States","volume":"198","author":"Hu","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 10","key":"10.1016\/j.ogc.2013.03.007_bib24","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/cncr.23744","article-title":"Understanding the burden of human papillomavirus-associated anal cancers in the US","volume":"113","author":"Joseph","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ogc.2013.03.007_bib25","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ogc.2013.03.007_bib26","unstructured":"Saraiya M. Burden of HPV-associated cancers in the United States. Presentation before the Advisory Committee on Immunization Practices (ACIP), February 24, 2011. Atlanta (GA): US Department of Health and Human Services, CDC; 2011. Available at: http:\/\/www.cdc.gov\/vaccines\/recs\/acip\/downloads\/mtg-slides-feb11\/11-2-hpv-rela-cancer.pdf. Accessed March 2, 2013."},{"key":"10.1016\/j.ogc.2013.03.007_bib27","unstructured":"Food and Drug Administration Center for Biologics Evaluation and Research. Briefing document for the Vaccines and Related Biological Products Advisory Committee. Subject: Male indication for Gardasil. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/UCM181361.pdf. Accessed September 24, 2009."},{"key":"10.1016\/j.ogc.2013.03.007_bib28","unstructured":"FDA. FDA approves new indication for Gardasil to prevent genital warts in men and boys. 2009 10\/16\/2009. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm187003.htm. Accessed October 20, 2009."},{"issue":"11","key":"10.1016\/j.ogc.2013.03.007_bib29","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s10350-004-6806-8","article-title":"Anal canal cancer: a population-based reappraisal","volume":"46","author":"Maggard","year":"2003","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ogc.2013.03.007_bib30","unstructured":"Howlader N, Noone AM, Krapcho M, et\u00a0al. SEER cancer statistics review, 1975-2008. Bethesda (MD): National Cancer Institute [based on November 2010 SEER data submission, posted to the SEER web site, 2011]. Available at: http:\/\/seer.cancer.gov\/csr\/1975_2008\/. Accessed December 7, 2012."},{"key":"10.1016\/j.ogc.2013.03.007_bib31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cncr.20364","article-title":"Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973\u20132000","volume":"101","author":"Johnson","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ogc.2013.03.007_bib32","unstructured":"Centers for Disease Control and Prevention. Human papilloma virus (HPV) associated cancers. Available at: http:\/\/www.cdc.gov\/cancer\/hpv\/statistics\/anal.htm. Accessed March 1, 2013."},{"key":"10.1016\/j.ogc.2013.03.007_bib33","series-title":"Highlights of prescribing information. Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18])","author":"Food and Drug Administration","year":"2011"},{"issue":"5","key":"10.1016\/j.ogc.2013.03.007_bib34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"50","key":"10.1016\/j.ogc.2013.03.007_bib35","first-page":"1705","article-title":"Recommendations for the quadrivalent human papillomavirus vaccine in males \u2013 Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Recomm Rep"},{"issue":"9","key":"10.1016\/j.ogc.2013.03.007_bib36","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(11)70213-3","article-title":"Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV 16\/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial","volume":"12","author":"Kreimer","year":"2011","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ogc.2013.03.007_bib37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ogc.2013.03.007_bib38","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against the human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.ogc.2013.03.007_bib39","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"FUTURE II Study Group","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ogc.2013.03.007_bib40","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A\u00a0pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"issue":"5","key":"10.1016\/j.ogc.2013.03.007_bib41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9580","key":"10.1016\/j.ogc.2013.03.007_bib42","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ogc.2013.03.007_bib43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ogc.2013.03.007_bib44","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A\u00a0review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30S","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ogc.2013.03.007_bib45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ogc.2013.03.007_bib46","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malag\u00f3n","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 10","key":"10.1016\/j.ogc.2013.03.007_bib47","doi-asserted-by":"crossref","first-page":"K62","DOI":"10.1016\/j.vaccine.2008.05.066","article-title":"Immunobiology of human papillomavirus infection and vaccination\u2013implications for second generation vaccines","volume":"26","author":"Stanley","year":"2008","journal-title":"Vaccine"},{"issue":"9447","key":"10.1016\/j.ogc.2013.03.007_bib48","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"27\u201328","key":"10.1016\/j.ogc.2013.03.007_bib49","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl 10","key":"10.1016\/j.ogc.2013.03.007_bib50","doi-asserted-by":"crossref","first-page":"K53","DOI":"10.1016\/j.vaccine.2008.06.002","article-title":"An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trials","volume":"26","author":"Schiller","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ogc.2013.03.007_bib51","unstructured":"Denny L, Hendricks B, Gordon C, et\u00a0al. Safety and immunogenicity of the HPV-16\/18 ASO4-adjuvanted vaccine in HIV positive women in South Africa. Abstract no. 599. Presented at AORTIC 7th International Conference. 2011."},{"key":"10.1016\/j.ogc.2013.03.007_bib52","unstructured":"Available at: http:\/\/www.clinicaltrials.gov\/ct2\/results?term=HPV+and+HIV&pg=1. Accessed January 26, 2013."},{"issue":"3","key":"10.1016\/j.ogc.2013.03.007_bib53","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.ogc.2013.03.007_bib54","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","article-title":"Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women","volume":"118","author":"Block","year":"2006","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.ogc.2013.03.007_bib55","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant","volume":"40","author":"Pedersen","year":"2007","journal-title":"J\u00a0Adolesc Health"},{"issue":"10","key":"10.1016\/j.ogc.2013.03.007_bib56","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/01.OLQ.0000078823.05041.9E","article-title":"Viral sexually transmitted disease vaccine acceptability among college students","volume":"30","author":"Boehner","year":"2003","journal-title":"Sex Transm Dis"},{"issue":"10","key":"10.1016\/j.ogc.2013.03.007_bib57","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum Vaccin"},{"issue":"12","key":"10.1016\/j.ogc.2013.03.007_bib58","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4161\/hv.7.12.18281","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years \u2013 Follow up from months 12-24 in a phase III randomized study of healthy women aged 18-45 years","volume":"7","author":"Einstein","year":"2011","journal-title":"Hum Vaccin"},{"issue":"12","key":"10.1016\/j.ogc.2013.03.007_bib59","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study","volume":"7","author":"Romanowski","year":"2011","journal-title":"Hum Vaccin"},{"issue":"19","key":"10.1016\/j.ogc.2013.03.007_bib60","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ogc.2013.03.007_bib61","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/CEJ.0b013e3282f75ea1","article-title":"HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy","volume":"17","author":"De Vuyst","year":"2008","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.ogc.2013.03.007_bib62","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jama.293.12.1471","article-title":"Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results","volume":"293","author":"Harris","year":"2005","journal-title":"JAMA"},{"issue":"Suppl 5","key":"10.1016\/j.ogc.2013.03.007_bib63","doi-asserted-by":"crossref","first-page":"F168","DOI":"10.1016\/j.vaccine.2012.06.045","article-title":"Human papillomavirus, human immunodeficiency virus and immunosuppression","volume":"30","author":"Denny","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.ogc.2013.03.007_bib64","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.vaccine.2010.10.051","article-title":"Worsening disparities in HPV vaccine utilization among 19-26 year old women","volume":"29","author":"Dempsey","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ogc.2013.03.007_bib65","first-page":"1018","article-title":"National, state, and local area vaccination coverage among adolescents aged 13\u201317 years\u2013-United States, 2009","volume":"59","author":"CDC","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"10.1016\/j.ogc.2013.03.007_bib66","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1542\/peds.2005-1381","article-title":"Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV","volume":"117","author":"Dempsey","year":"2006","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.ogc.2013.03.007_bib67","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijgo.2008.07.005","article-title":"Young multiethnic women\u2019s attitudes toward the HPV vaccine and HPV vaccination","volume":"103","author":"Wong","year":"2008","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"10.1016\/j.ogc.2013.03.007_bib68","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00128360-200407000-00005","article-title":"Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents","volume":"8","author":"Davis","year":"2004","journal-title":"J\u00a0Low Genit Tract Dis"},{"issue":"3","key":"10.1016\/j.ogc.2013.03.007_bib69","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jadohealth.2005.06.004","article-title":"Predictors of STI vaccine acceptability among parents and their adolescent children","volume":"37","author":"Zimet","year":"2005","journal-title":"J\u00a0Adolesc Health"},{"issue":"6","key":"10.1016\/j.ogc.2013.03.007_bib70","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1542\/peds.2008-1536","article-title":"Mothers\u2019 intention for their daughters and themselves to receive the human papillomavirus vaccine: a national study of nurses","volume":"123","author":"Kahn","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ogc.2013.03.007_bib71","series-title":"Panel recommends a 2nd cervical cancer vaccine as alternative for girls and young women","author":"Stobbe","year":"2009"},{"key":"10.1016\/j.ogc.2013.03.007_bib72","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/GCO.0b013e3283567005","article-title":"Human papillomavirus vaccine in adolescent women: a 2012 update","volume":"24","author":"Etter","year":"2012","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.ogc.2013.03.007_bib73","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ogc.2013.03.007_bib74","doi-asserted-by":"crossref","first-page":"40470","DOI":"10.1155\/IDOG\/2006\/40470","article-title":"Epidemiology and natural history of human papillomavirus infections in the female genital tract","volume":"2006","author":"Ault","year":"2006","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ogc.2013.03.007_bib75","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0025-6196(11)60898-7","article-title":"Human papillomavirus and vaccination","volume":"83","author":"Huang","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.ogc.2013.03.007_bib76","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ypmed.2008.11.010","article-title":"Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, national immunization survey-adult 2007","volume":"48","author":"Jain","year":"2009","journal-title":"Prev Med"},{"issue":"4","key":"10.1016\/j.ogc.2013.03.007_bib77","first-page":"66","article-title":"Adult vaccination coverage \u2014 United States, 2010","volume":"61","author":"Williams","year":"2012","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"10.1016\/j.ogc.2013.03.007_bib78","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.vaccine.2009.10.133","article-title":"Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university based health system","volume":"28","author":"Dempsey","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ogc.2013.03.007_bib79","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.1016\/j.vaccine.2008.07.056","article-title":"Prophylactic HPV vaccines: new interventions for cancer control","volume":"26","author":"Barr","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ogc.2013.03.007_bib80","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1475-9276-10-27","article-title":"Global challenges of implementing human papillomavirus vaccines","volume":"10","author":"Graham","year":"2011","journal-title":"Int J Equity Health"},{"key":"10.1016\/j.ogc.2013.03.007_bib81","series-title":"GAVI welcomes lower prices for life-saving vaccines","year":"2011"},{"issue":"Suppl 5","key":"10.1016\/j.ogc.2013.03.007_bib82","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1469-0691.2012.03946.x","article-title":"Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges","volume":"18","author":"Poljak","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ogc.2013.03.007_bib83","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2471\/BLT.11.08986","article-title":"Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries","volume":"89","author":"LaMontagne","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ogc.2013.03.007_bib84","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","article-title":"Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data","volume":"11","author":"Donovan","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ogc.2013.03.007_bib85","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/sextrans-2011-050234","article-title":"The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme","volume":"87","author":"Read","year":"2011","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.ogc.2013.03.007_bib86","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early impact of the HPV vaccination program on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ogc.2013.03.007_bib87","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/jnci\/djr053","article-title":"For cancers caused by HPV, two vaccines were just the beginning","volume":"103","author":"Peres","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ogc.2013.03.007_bib88","doi-asserted-by":"crossref","first-page":"E139","DOI":"10.1002\/ijc.27831","article-title":"Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2","volume":"132","author":"Seitz","year":"2013","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ogc.2013.03.007_bib89","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.virol.2012.09.006","article-title":"Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2","volume":"434","author":"Nakao","year":"2012","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.ogc.2013.03.007_bib90","doi-asserted-by":"crossref","first-page":"e39741","DOI":"10.1371\/journal.pone.0039741","article-title":"Development of AAVLP(HPV16\/31L2) particles as broadly protective HPV vaccine candidate","volume":"7","author":"Nieto","year":"2012","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.ogc.2013.03.007_bib91","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2012.03.009","article-title":"Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb\/c mice","volume":"30","author":"Yoon","year":"2012","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.ogc.2013.03.007_bib92","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/ijc.24634","article-title":"EUROGIN 2008 roadmap on cervical cancer prevention","volume":"125","author":"Franceschi","year":"2009","journal-title":"Int J Cancer"},{"issue":"22","key":"10.1016\/j.ogc.2013.03.007_bib93","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/jnci\/djs395","article-title":"Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis","volume":"104","author":"Van de Velde","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ogc.2013.03.007_bib94","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/14712598.8.4.421","article-title":"Therapeutic human papillomavirus vaccines: current clinical trials and future directions","volume":"8","author":"Hung","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ogc.2013.03.007_bib95","doi-asserted-by":"crossref","first-page":"e1401","DOI":"10.1136\/bmj.e1401","article-title":"Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data","volume":"344","author":"Joura","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.ogc.2013.03.007_bib96","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"FUTURE I\/II Study Group","year":"2010","journal-title":"BMJ"},{"issue":"9576","key":"10.1016\/j.ogc.2013.03.007_bib97","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ogc.2013.03.007_bib98","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years","volume":"199","author":"Brown","year":"2009","journal-title":"J\u00a0Infect Dis"},{"issue":"9686","key":"10.1016\/j.ogc.2013.03.007_bib99","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"}],"container-title":["Obstetrics and Gynecology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854513000326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854513000326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T03:30:08Z","timestamp":1539660608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889854513000326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0889854513000326"],"URL":"https:\/\/doi.org\/10.1016\/j.ogc.2013.03.007","relation":{},"ISSN":["0889-8545"],"issn-type":[{"value":"0889-8545","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}